Takuya Egami

Author PubWeight™ 9.74^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.	Anticancer Res	2008	1.06
2	Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells.	Cancer Sci	2009	1.01
3	Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer.	World J Gastroenterol	2006	0.95
4	LIM only 4 is overexpressed in late stage pancreas cancer.	Mol Cancer	2008	0.94
5	S100P is an early developmental marker of pancreatic carcinogenesis.	Clin Cancer Res	2006	0.92
6	Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer.	Anticancer Res	2007	0.90
7	Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.	Cancer Lett	2010	0.84
8	Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells.	Anticancer Res	2011	0.81
9	Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway.	Cancer Sci	2010	0.81
10	Quantitative analysis of hTERT mRNA levels in cells microdissected from cytological specimens.	Cancer Sci	2008	0.81
11	Midkine mRNA is overexpressed in pancreatic cancer.	Dig Dis Sci	2008	0.81